The Top 5 Biosimilar Articles for the Week of January 11

January 15, 2021

Here are the top 5 biosimilar articles for the week of January 11, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of January 11, 2021.

Number 5: Rapid health care reforms in China have led to a regulatory environment that improves conditions for biosimilar development and approval, according to Lawrence A. Hill, PharmD, MBA, RPh, BCPS, CEO of Gan & Lee Pharmaceuticals

Number 4: Authors of a review of studies on machine learning speculated that artificial intelligence could improve the selection of biosimilars for therapy.

Number 3: Investigators have reported pharmacokinetic (PK) findings that confirm the biosimilarity of Viatris’ trastuzumab biosimilar candidate (Ogivri) to reference Herceptin.

Number 2: Authors of a review found that biosimilar uptake and market share are not in themselves sufficient to establish whether these agents will lead to savings.

Number 1: Multiple biosimilar developers have obtained FDA approval for adalimumab biosimilars but won’t be able to enter the market until 2023. One question on experts' minds is whether these approved biosimilars will still be relevant 2 years from now.

To read all of these articles and more, visit